Results 231 to 240 of about 54,066 (258)
Some of the next articles are maybe not open access.
Outcomes in AML patients receiving HMA + venetoclax combination with prior HMA exposure.
Journal of Clinical Oncology, 2021e19011 Background: Venetoclax (Ven) is a BCL-2 inhibitor approved in combination with hypomethylating agents (HMAs) in newly diagnosed AML patients who are not candidates for intensive induction based on impressive response rates (CR+CRi of 66.4%) and median overall survival (14.7 months) compared to HMA therapy alone (DiNardo CD, NEJM, 2020).
Bakos Keegan Jonathan +8 more
openaire +1 more source
Novel therapies upon failure of HMA plus venetoclax
Hematology, 2023Abstract The efficacy and tolerability of the combination of hypomethylating agents with venetoclax (HMA-VEN) in patients with newly diagnosed acute myeloid leukemia has been a practice-changing milestone in the field. However, treatment failure and relapse remain major barriers to prolonged survival.
Onyee, Chan, Alison R, Walker
openaire +2 more sources
The Huge Microphone Array (HMA)
The Journal of the Acoustical Society of America, 1997The Huge Microphone Array (HMA) is a collaborative effort between Brown University and Rutgers University that started in February 1994 to design, construct, debug, and test a real-time 512-microphone array system and to develop algorithms for use on it.
Harvey F. Silverman +2 more
openaire +1 more source
Investigation into three-layered HMA mixtures
Composites Part B: Engineering, 2006Abstract Hot-mix asphalt (HMA) mixtures consist of three phases: aggregate, asphalt binder (mastic) and air voids, of which the first two (aggregate and asphalt binder) provide the structure that withstands various kinds of loading. Due to the nature of high inhomogeneity between aggregate and asphalt binder, significant stress and strain ...
Baoshan Huang, Guoqiang Li, Xiang Shu
openaire +1 more source
Treatment with Hypomethylating Agents (HMA)
2018In 1993 Silverman and coworkers [1] reported on a phase 2 trial on 43 patients with higher-risk MDS (medullary blast count >10%) using 75 mg/m2 5-Azacytidine (5-Aza) for 7 days every 28 days for 6 cycles. Forty-nine percent of the patients responded, with 12% CR (CR and PR 37%, and 5% improved hematologically without achieving CR or PR), and 51% were ...
Ulrich Germing, Pierre Fenaux
openaire +1 more source
Beyond HMAs: Novel Targets and Therapeutic Approaches
Seminars in HematologyMyelodysplastic syndromes/neoplasms (MDS) constitute a heterogeneous group of clonal hematopoietic disorders with extremely variable clinical features and outcomes. Management of MDS is largely based on risk stratification of patients into either lower-risk or higher-risk categories using the International Prognostic Scoring System-Revised and, more ...
Ted M. Getz +7 more
openaire +2 more sources
Analytical Modeling of Three-Layered HMA Mixtures
International Journal of Geomechanics, 2007This paper presents the analytical modeling of three-layered hot mix asphalt (HMA) mixtures. Conventional HMA mixtures can be regarded as a two-layered composite with asphalt-coated aggregate particles dispersed in an equivalent medium. The three-layered HMA mixtures can be constructed by introducing an intermediate layer of stiff binder coated over ...
Baoshan Huang +3 more
openaire +1 more source
Smoothness Index Relationships for HMA Pavements
2003A recent Federal Highway Administration survey indicated that 48 states and Puerto Rico use smoothness specifications for hot-mix asphalt (HMA) pavement construction. As this is a relatively new concept, many states have adapted the Portland cement concrete pavement specifications of Profile Index using the standard 5-mm blanking band (PI5.0) for use ...
LD Evans +4 more
openaire +1 more source